Desonide
 Desonide cream

drug-information.ru

|Desonide Desonide cream

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Desonide

Dosage Form: Ointment

For Dermatological Use Only - Not for Ophthalmic Use    Rx Only

Description

Desonide Ointment contains Desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-, (11β,16 α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents.

Chemically, Desonide, the active ingredient in Desonide Ointment, is C24H32O6. It has the following structural formula:

Desonide has the molecular weight of 416.51. It is a white to off-white powder. The solubility of Desonide in distilled water saturated with ether is 184 mg/L.

Each gram of Desonide Ointment contains 0.5 milligrams of Desonide microdispersed in a base of white petrolatum.

Desonide - Clinical Pharmacology

Like other topical corticosteroids, Desonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called, lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity, of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Studies performed with Desonide Ointment indicate that it is in the low range of potency as compared with other topical corticosteroids.

Indications and Usage for Desonide

Desonide Ointment is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

It should not be used for longer than two weeks unless directed by a physician.

Contraindications

Desonide Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Precautions

General

Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing"s syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.

Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression.

This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppressions.

No specific studies relevant to potential HPA suppression have been conducted with Desonide Ointment.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS -Pediatric use)

If irritation develops, Desonide Ointment should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Desonide Ointment should be discontinued until the infection has been adequately controlled.

Desonide Ointment should not be used in the presence of infection at the treatment site, hypersensitivity to corticosteroids, or pre-existing skin atrophy.

Desonide Ointment should not be used in the eyes.

FOR EXTERNAL USE ONLY.

Information for Patients

Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  2. This medication should not be used for any disorder other than that for which it was prescribed.
  3. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.
  4. Patients should report to their physician any signs of local adverse reactions.

Laboratory Tests

The following test may be helpful in evaluating patients for HPA axis suppression:

 
ACTH stimulation test
 
A.M. plasma cortisol test
 
Urinary free cortisol test

Carcinogenesis, mutagenesis, and impairment of fertility

Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of Desonide Ointment.

Pregnancy

Teratogenic effects

Pregnancy category C

Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with Desonide Ointment. It is also not known whether Desonide Ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Desonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Desonide Ointment is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing"s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment.

Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.

HPA axis suppression, Cushing"s syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Adverse Reactions

In controlled clinical trials, the total incidence of adverse reactions associated with the use of Desonide Ointment was approximately 6 %. These were erythema, induration, pruritus, irritation, oiliness, and peripheral edema.

The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.

Overdosage

Topically applied Desonide Ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

Desonide Dosage and Administration

Desonide Ointment should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.

As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

Desonide Ointment should not be used with occlusive dressings.

How is Desonide Supplied

Desonide Ointment, 0.05% is supplied in 15 and 60 gram tubes.

Store between 15° and 30° C (59° and 86° F).

DISTRIBUTED BY PERRIGO, ALLEGAN, MI 49010

D423
I423-N R 1005


Desonide (Desonide)
PRODUCT INFO
Product Code 45802-423 Dosage Form OINTMENT
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Desonide (Desonide) Active 0.5 MILLIGRAM  In 1 GRAM
white petrolatum Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 45802-423-35 15 GRAM In 1 TUBE None
2 45802-423-37 60 GRAM In 1 TUBE None

Revised: 02/2007





Where can I get more information about Desonide Desonide cream ? We recommend to use www.Drugs.com

Typical mistypes for Desonide Desonide cream
sesonide desonide cream, xesonide desonide cream, cesonide desonide cream, fesonide desonide cream, resonide desonide cream, eesonide desonide cream, dwsonide desonide cream, dssonide desonide cream, ddsonide desonide cream, drsonide desonide cream, d4sonide desonide cream, d3sonide desonide cream, deaonide desonide cream, dezonide desonide cream, dexonide desonide cream, dedonide desonide cream, deeonide desonide cream, dewonide desonide cream, desinide desonide cream, desknide desonide cream, deslnide desonide cream, despnide desonide cream, des0nide desonide cream, des9nide desonide cream, desobide desonide cream, desomide desonide cream, desojide desonide cream, desohide desonide cream, desonude desonide cream, desonjde desonide cream, desonkde desonide cream, desonode desonide cream, deson9de desonide cream, deson8de desonide cream, desonise desonide cream, desonixe desonide cream, desonice desonide cream, desonife desonide cream, desonire desonide cream, desoniee desonide cream, desonidw desonide cream, desonids desonide cream, desonidd desonide cream, desonidr desonide cream, desonid4 desonide cream, desonid3 desonide cream, desonide sesonide cream, desonide xesonide cream, desonide cesonide cream, desonide fesonide cream, desonide resonide cream, desonide eesonide cream, desonide dwsonide cream, desonide dssonide cream, desonide ddsonide cream, desonide drsonide cream, desonide d4sonide cream, desonide d3sonide cream, desonide deaonide cream, desonide dezonide cream, desonide dexonide cream, desonide dedonide cream, desonide deeonide cream, desonide dewonide cream, desonide desinide cream, desonide desknide cream, desonide deslnide cream, desonide despnide cream, desonide des0nide cream, desonide des9nide cream, desonide desobide cream, desonide desomide cream, desonide desojide cream, desonide desohide cream, desonide desonude cream, desonide desonjde cream, desonide desonkde cream, desonide desonode cream, desonide deson9de cream, desonide deson8de cream, desonide desonise cream, desonide desonixe cream, desonide desonice cream, desonide desonife cream, desonide desonire cream, desonide desoniee cream, desonide desonidw cream, desonide desonids cream, desonide desonidd cream, desonide desonidr cream, desonide desonid4 cream, desonide desonid3 cream, desonide desonide xream, desonide desonide vream, desonide desonide fream, desonide desonide dream, desonide desonide ceeam, desonide desonide cdeam, desonide desonide cfeam, desonide desonide cteam, desonide desonide c5eam, desonide desonide c4eam, desonide desonide crwam, desonide desonide crsam, desonide desonide crdam, desonide desonide crram, desonide desonide cr4am, desonide desonide cr3am, desonide desonide crezm, desonide desonide cresm, desonide desonide crewm, desonide desonide creqm, desonide desonide crean, desonide desonide creak, desonide desonide creaj, esonide desonide cream, dsonide desonide cream, deonide desonide cream, desnide desonide cream, desoide desonide cream, desonde desonide cream, desonie desonide cream, desonid desonide cream, desonide desonide cream, desonide desonide cream, desonide esonide cream, desonide dsonide cream, desonide deonide cream, desonide desnide cream, desonide desoide cream, desonide desonde cream, desonide desonie cream, desonide desonid cream, desonide desonidecream, desonide desonide ream, desonide desonide ceam, desonide desonide cram, desonide desonide crem, desonide desonide crea, edsonide desonide cream, dseonide desonide cream, deosnide desonide cream, desnoide desonide cream, desoinde desonide cream, desondie desonide cream, desonied desonide cream, desonid e desonide cream, desonide desonide cream, desonide d esonide cream, desonide edsonide cream, desonide dseonide cream, desonide deosnide cream, desonide desnoide cream, desonide desoinde cream, desonide desondie cream, desonide desonied cream, desonide desonid ecream, desonide desonidec ream, desonide desonide rceam, desonide desonide ceram, desonide desonide craem, desonide desonide crema, ddesonide desonide cream, deesonide desonide cream, dessonide desonide cream, desoonide desonide cream, desonnide desonide cream, desoniide desonide cream, desonidde desonide cream, desonidee desonide cream, desonide desonide cream, desonide desonide cream, desonide ddesonide cream, desonide deesonide cream, desonide dessonide cream, desonide desoonide cream, desonide desonnide cream, desonide desoniide cream, desonide desonidde cream, desonide desonidee cream, desonide desonide cream, desonide desonide ccream, desonide desonide crream, desonide desonide creeam, desonide desonide creaam, desonide desonide creamm, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved